Skip to main content
HR 3925 105th Congress House Health Ambulatory care Australia Business income tax Business records Canada Commerce Congress Congressional reporting requirements Cost accounting Costs Drug industry Drugs Economics and Public Finance Electronic data interchange Europe European Union Federal advisory bodies Finance and Financial Sector Foreign Trade and International Finance

Prescription Drug Price Monitoring Commission Act of 1998

Introduced: May 21, 1998 See on congress.gov
Sign in to write a letter Sign in to watch
 Everywhere this bill has been 6 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Jun 5, 1998
Referred to the Subcommittee on Health and Environment, for a period to be subsequently determined by the Chairman.
Jun 1, 1998
Referred to the Subcommittee on Health.
May 21, 1998
Referred to House Commerce
May 21, 1998
Referred to the Committee on Ways and Means, and in addition to the Committee on Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
May 21, 1998
Referred to House Ways and Means
May 21, 1998
Introduced in House
 Plain-English summary Congressional Research Service

Prescription Drug Price Monitoring Commission Act of 1998 - Establishes the Prescription Drug Price Monitoring Commission which shall conduct specified studies concerning U.S. pharmaceutical prices, including the establishment of a pharmaceutical products price review board. Terminates the Commission on a specified date.

Directs the Secretary of Health and Human Services to study and report on Federal subsidies and incentives provided to the pharmaceutical industry.

Amends title XIX (Medicaid) of the Social Security Act to require drug manufacturers participating in the Medicaid rebate program to report within a certain time after the end of each calendar year (currently, after each rebate period) on the average price at which the manufacturer sold each covered outpatient drug in Canada, Australia, Mexico, and the European Union countries.

What's happening now June 5, 1998

Referred to the Subcommittee on Health and Environment, for a period to be subsequently determined by the Chairman.

 Committees of jurisdiction 4
 Cosponsors 3
All 3 Democratic 2 Independent 1